BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23101951)

  • 1. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data.
    Qu Y; Jacober SJ; Zhang Q; Wolka LL; DeVries JH
    Diabetes Technol Ther; 2012 Nov; 14(11):1008-12. PubMed ID: 23101951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
    Buse JB; Wolffenbuttel BH; Herman WH; Shemonsky NK; Jiang HH; Fahrbach JL; Scism-Bacon JL; Martin SA
    Diabetes Care; 2009 Jun; 32(6):1007-13. PubMed ID: 19336625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
    Jovanovič L; Peters AL; Jiang HH; Hardin DS
    Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P; Trautmann M; Arora V; Sun B; Anderson JH
    Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus.
    Kovatchev B; Umpierrez G; DiGenio A; Zhou R; Inzucchi SE
    J Diabetes Sci Technol; 2015 Jun; 9(6):1227-35. PubMed ID: 26078255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70.
    Li Y; Li Q; Li CJ; Wang CJ; Zheng YM; Issa M; Zhang J
    Chin Med J (Engl); 2009 Nov; 122(21):2540-6. PubMed ID: 19951567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.
    Sakharova OV; Lleva RR; Dziura JD; Spollett GR; Howell SK; Beisswenger PJ; Inzucchi SE
    J Diabetes Complications; 2012; 26(4):333-8. PubMed ID: 22541894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Starting an insulin regimen with insulin lispro mix 25 versus glargine insulin for type 2 diabetes].
    Fernández Landó L; Massari F; Oviedo A; Jiang H
    Medicina (B Aires); 2012; 72(3):235-42. PubMed ID: 22763161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
    de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
    Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
    Giugliano D; Tracz M; Shah S; Calle-Pascual A; Mistodie C; Duarte R; Sari R; Woo V; Jiletcovici AO; Deinhard J; Wille SA; Kiljanski J
    Diabetes Care; 2014 Feb; 37(2):372-80. PubMed ID: 24170763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications.
    Milicevic Z; Hancu N; Car N; Ivanyi T; Schwarzenhofer M; Jermendy G
    Exp Clin Endocrinol Diabetes; 2009 May; 117(5):223-9. PubMed ID: 19301232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.
    Perriello G; Caputo S; De Pergola G; Di Carlo A; Grassi G; Lapolla A; Pata P; Solerte SB; Zaccardi F
    Expert Opin Pharmacother; 2011 Nov; 12(16):2449-55. PubMed ID: 21988213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.
    Hirsch IB; Yuan H; Campaigne BN; Tan MH
    Endocr Pract; 2009; 15(4):343-8. PubMed ID: 19454394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.